arrow
H

Hervé Avet-Loiseau

UCSF Helen Diller Family Comprehensive Cancer Center
H指数:112
被引数:5.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma

多模态抗原逃逸以GPRC5D-targeted多发性骨髓瘤中的T细胞接合器

2026-01-150
OAAI
Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM)

通过大型开放式网络课程(MOOC)为多发性骨髓瘤患者及照护者提供以患者为中心的教育:法国多发性骨髓瘤患者协会(AF3M)和法语骨髓瘤协作组(IFM)关于知识增长的描述性研究

2026-01-010
PRE
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience

35年专注于高剂量疗法和自体干细胞移植的学术研究:法国骨髓瘤研究组(IFM)的经验

2025-10-240
OA
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial

脆弱及新诊断多发性骨髓瘤患者中地塞米松减量方案联合达拉珠单抗和来那度胺的安全性与有效性(IFM2017-03):一项III期、开放标签、多中心、随机对照试验

2025-09-290
OAAI
High-risk genomic consensus validation in newly diagnosed multiple myeloma patients using next-generation sequencing

使用下一代测序对 newly diagnosed multiple myeloma 患者进行高风险基因组共识验证

Blood
IF23.1
2025-09-260
PRE
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study

从ide-cel早期复发后使用靶向BCMA的双特异性抗体治疗效果不佳:一项法国真实世界研究

2025-09-200
OAAI
Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post-hoc analysis of BENEFIT

移植不适格的套细胞瘤患者在使用三联/四联疗法时的血栓栓塞:BENEFIT研究的后续分析

2025-06-140
PRE
Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 study
2024-11-140
OAAI
Increased Expression of the Sialyltransferase GeneST3GAL1Predicts Lack of Sustained MRD Negativity and Increased Risk of Progression in Newly Diagnosed, Transplant Eligible Multiple Myeloma Patients in the Maintenance/Observation Phase of Cassiopeia Study

ST3GAL1唾液酸转移酶基因表达增加预测卡西奥佩亚研究中新诊断、适合移植的多发性骨髓瘤患者在维持/观察期缺乏持续的微小残留病阴性及进展风险增加

BLOOD
IF23.1
2024-11-050
PRE
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
2024-06-038
OAAI
Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study
2024-06-012
PRE
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival
2023-12-043
OAAI